Biopharmaceuticals

Biopharmaceuticals, comprising large molecule drugs that are traditional pharmaceuticals in size, fall into two categories: biologics and biosimilars. Biologics, generated from large protein-derived molecules cultivated in cells and purified into active agents, stand alongside biosimilars, similar to generic conventional drugs but highly similar to approved biologicals. Administered through injections or infusions, biopharmaceuticals offer treatment options for individuals grappling with conditions for which existing therapies offer limited efficacy.

Biopharmaceuticals represent a cutting-edge class of drugs derived from biological sources, including living cells and microorganisms. These drugs are designed to treat various medical conditions, ranging from chronic diseases to rare disorders, by harnessing the power of biotechnology. Unlike traditional pharmaceuticals, biopharmaceuticals are often large, complex molecules, such as proteins and monoclonal antibodies, produced through advanced genetic engineering techniques. One notable feature of biopharmaceuticals is their ability to target specific molecules involved in disease processes with high precision, leading to enhanced therapeutic outcomes and reduced side effects. The ongoing advancements in biopharmaceutical development underscore their pivotal role in shaping the future of healthcare.